Latest news with #TorrentPharmaceuticals
&w=3840&q=100)
Business Standard
10 hours ago
- Business
- Business Standard
Street bullish on Torrent Pharma's prospects post in-line Q1 FY26
Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges Devangshu Datta Mumbai Listen to This Article Torrent Pharmaceuticals (Torrent) reported revenue and EBITDA that met consensus for the April-June quarter (Q1) of FY26. However, earnings were lower due to reduced other income. Torrent saw robust growth in Brazil in FY25, and the momentum continued into Q1FY26. However, currency volatility hurt earnings. There was also improved performance in the domestic formulation (DF) segment, while Germany faced headwinds. New launches are expected to drive growth in the US generics business. Sales grew 11.2 per cent year-on-year (YoY) to ₹3,180 crore. Domestic formulation revenue grew 10.8 per cent YoY to ₹1,810 crore (57 per cent of sales). US generics
Business Standard
17 hours ago
- Business
- Business Standard
Torrent Pharma gains as Q1 earnings impress; foreign broker hikes target
Torrent Pharmaceuticals jumped 2.95% to Rs 3,732 after the company posted a robust performance for the first quarter of FY26, with growth firing across both domestic and international markets. The pharma major reported a net profit of Rs 548 crore, marking a 20% year-on-year increase, driven by resilient revenues and steady margins. Revenue for the quarter stood at Rs 3,178 crore, an 11% rise over Q1 FY25, supported by improved operational leverage. International markets played a key role in the growth story. Sales in the United States rose 19% to Rs 308 crore. India, Torrents largest market, contributed Rs 1,811 crore, growing 11% year-on-year. Brazil matched that growth with an 11% rise, while Germany posted a 9% increase. Revenue from other global markets was also healthy, rising 10% YoY. On the operational front, EBITDA grew 14% YoY to Rs 1,032 crore, translating into a margin of 32.5%. Adjusting for one-time acquisition-related expenses of Rs 15 crore, the margin edged higher to 32.9%. Gross margins remained firm at 76% in Q1 FY26. The company also continued to back its R&D engine, spending Rs 157 crore during the quarter, a 16% increase over last year, while maintaining the R&D-to-sales ratio at 5%. Torrent's performance drew praise from analysts. A foreign brokerage firm raised its price target on the stock to Rs 4,380 from Rs 4,000, citing the quarter as "healthy and in-line," with "solid traction across geographies." The firm maintained its 'Buy' rating, reflecting optimism over the companys steady execution and global growth outlook. Torrent Pharmaceuticals is the flagship of the Torrent Group and ranks seventh in the Indian pharmaceutical market. It is among the top five players in key therapeutic areas such as cardiovascular, gastrointestinal, central nervous system, and cosmo-dermatology. With nearly 76% of its India business coming from chronic and sub-chronic therapies, Torrent remains a focused, specialty-driven player.
Time of India
19 hours ago
- Business
- Time of India
Torrent Pharma Q1 net profit rises 20% on broad-based growth
AHMEDABAD: Homegrown pharma major, Torrent Pharmaceuticals, reported a 20% year-on-year increase in net profit to Rs 548 crore for the first quarter of FY26. This growth was driven by strong performance across its India, US, and Brazil markets. The company's consolidated revenue grew 11% to Rs 3,178 crore, while operating EBITDA rose 14% to Rs 1,032 crore. Adjusted for one-time acquisition-related costs of Rs 15 crore, EBITDA stood at Rs 1,047 crore, with a margin of 32.9%. The gross margin remained stable at 76%, and R&D spend grew 16% to Rs 157 crore. The India business, which contributed over half of its total sales, recorded revenues of Rs 1,811 crore, up 11% year-on-year, led by strong growth in chronic therapies. Torrent's chronic portfolio expanded 13%, outpacing the Indian Pharmaceutical Market's 9% growth, as per AIOCD data. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad In the US, Torrent Pharma revenues rose 19% to Rs 308 crore, with new launches achieving targeted market share. Brazil revenues grew 11% to Rs 218 crore, or 16% in constant currency terms, bolstered by key brand performance and new product introductions. Germany saw 9% growth to Rs 308 crore, though constant currency sales rose just 1% due to supply disruptions at a third-party facility. Despite this, Torrent maintained steady margins and expects continued growth across geographies.
Business Standard
a day ago
- Business
- Business Standard
Torrent Pharma Q1 profit rises 20% to ₹548 cr on strong global sales
Torrent Pharmaceuticals on Monday said its consolidated net profit increased 20 per cent year-on-year to ₹548 crore in the June quarter, driven by strong sales across markets, including India and the US. The drug firm reported a net profit of ₹457 crore in the April-June quarter of the last fiscal. Revenue from operations rose to ₹3,178 crore in the June quarter compared with ₹2,859 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The drug maker said its India revenues rose by 11 per cent year-on-year to ₹1,811 crore in the April-June period, led by outperformance in focus therapies. The US business revenues stood at ₹308 crore in the June quarter, by 19 per cent year-on-year, it added. Similarly, revenue in Brazil rose by 11 per cent to ₹218 crore, the company stated. Its sales in Germany were up 9 per cent year-on-year to ₹308 crore in the June quarter against the same period last year. Shares of Torrent Pharma settled 0.75 per cent higher at ₹3,629.50 apiece on the BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Torrent Pharma Q1 results: PAT up 20% on robust sales across territories
Torrent Pharmaceuticals on Monday reported a 20 per cent year-on-year (Y-o-Y) rise in consolidated net profit for the June quarter (Q1 FY26) to ₹548 crore, up from ₹457 crore in Q1 FY25, on the back of robust sales across territories. The company's revenue from operations rose to ₹3,178 crore in Q1 FY26, reflecting an 11 per cent Y-o-Y growth from ₹2,815 crore in Q1 FY25. This includes an 11 per cent increase in the company's India revenues, which rose to ₹1,811 crore, led by outperformance in focus therapies. Torrent's chronic business grew at 13 per cent, compared to the Indian Pharma Market's (IPM's) growth of 9 per cent. The Ahmedabad-based pharma major added that it has 21 brands in the top 500 brands in the IPM, with 14 brands having sales of more than ₹100 crore. 'The figure includes acquisition-related one-off expenses of ₹15 crore,' the company said in a statement. Apart from the domestic market, the company also saw growth in revenue from foreign markets. Torrent's revenue from the US market rose by 19 per cent to ₹308 crore, up from ₹259 crore in Q1 FY25. Similarly, revenues from the Brazil market rose by 11 per cent Y-o-Y in Q1 FY26 to ₹218 crore, up from ₹196 crore in the same period last year. The company attributed this growth to the performance of top brands, new launches, and growth in the generic segment. On Monday, Torrent's shares rose marginally by 0.75 per cent, ending the day's trade at ₹3,629.50 apiece on the Bombay Stock Exchange.
